Opinion
|
|||||||
P&G announces very weak 3rd quarter results to Wall Street; stock drops 5% in two days, 15% off all time peak, and flat with its pre-pullback 2007 and post-pullback 2010 levels. Â Essentially P&G has been dead money for over five years.Insights
-
May 17, 2012
Retrospective meta-analysis of statin use in low risk people shows favorable risk/benefit, however study not representative of the risk/benefit if sold OTC.
-
May 16, 2012
FDA delays game changing regulations to allow industry to comply; testing and reformulation burden heavy.
-
May 15, 2012
Avon fails to act on sweetened Coty bid at $24.75/share; new Avon CEO chooses not to reply after two weeks on the job; Coty moves on.
-
May 10, 2012
After years of centripetal centralization of its offices and acquisitions in Cincinnati P&G continues its centrifugal migration to Asia and Europe; P&G has tried multiple solutions to global markets since 1985.
-
May 7, 2012
Obama care regulations create chaos and jack up cost by having physicians write prescriptions for non-prescription drugs! Â Back to the future 2012!
-
May 7, 2012
Canadian review of 17 colds studies claims thst oral zinc reduces duration of colds; nausea common side effect.
Sign up for our Email Alerts
More opinions
More insights
- Avon: The Rise and Fall of a Beauty Icon, Fortune
- Out of The Mire?, The Economist
- Novartis Tries More Exec Level OTC Switches, Pharmalot
- Glaxo To Sell Non-Core OTC Brands To Aspen, Wall Street Journal
- J&J: The Gang That Couldn’t Shoot Straight, Pharmalot
- Popular J.&J. Drugs May Not Return Until 2013, New York Times
